Abstract
DESPITE its widespread distribution on both lymphoid and myeloid cells, the biological role of the low-affinity immuno-globulin-G receptor, FcγRII, is not fully understood. Defects in this receptor or its signalling pathway in B cells result in perturbations in immune-complex-mediated feedback inhibition of antibody production1–6. We now report that FcγRII-deficient animals display elevated immunoglobulin levels in response to both thymus-dependent and thymus-independent antigens. Additionally, the effector arm of the allergic response is perturbed in these mice. Mast cells from FcγRII−/− are highly sensitive to IgG-triggered degranulation, in contrast to their wild-type counterparts. FcγRII-deficient mice demonstrate an enhanced passive cutaneous analphylaxis reaction, the result of a decreased threshold for mast-cell activation by FcγRIII cross-linking. These results demonstrate that FcγRII acts as a general negative regulator of immune-complex-triggered activation in vivo for both the afferent and efferent limbs of the immune response. Exploiting this property offers new therapeutic opportunities for the treatment of allergic and autoimmune disorders.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Philipps, N. E. & Parker, D. C. J. Immun. 132, 627–632 (1984).
Amigorena, S. et al. Science 243, 378–380 (1992).
Choquet, D. et al. J. Cell Biol. 121, 355–363 (1993).
Muta, T. et al. Nature 368, 70–73 (1994).
D'Ambrosio, D. et al. Science 268, 293–297 (1995).
Pani, G. et al. J. exp. Med. 181, 2077–2084 (1995).
Ravetch, J. V. Cell 78, 553–560 (1994).
Daeron, M. et al. J. Clin. Invest. 95, 577–585 (1995).
Weinshank, R. L., Luster, A. D. & Ravetch, J. V. J. exp. Med. 167, 1909–1925 (1988).
Lobell, R. B. et al. J. biol. Chem. 268, 1207–1212 (1993).
Bijsterbosch, M. K. & Klaus, G. B. J. exp. Med. 162, 1825–1836 (1985).
Wilson, H. A. et al. J. Immun. 138, 1712–1718 (1987).
Qui, W. Q. et al. Science 248, 732–735 (1990).
Daeron, M. et al. J. Immun. 149, 1365–1373 (1992).
Takai, T. et al. Cell 76, 519–529 (1994).
Sylvestre, D. L. & Ravetch, J. V. Science 265, 1095–1098 (1994).
Daëron, S., et al. Immunity 3, 635–646 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takai, T., Ono, M., Hikida, M. et al. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379, 346–349 (1996). https://doi.org/10.1038/379346a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/379346a0
- Springer Nature Limited
This article is cited by
-
A subset of type-II collagen-binding antibodies prevents experimental arthritis by inhibiting FCGR3 signaling in neutrophils
Nature Communications (2023)
-
CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study
Journal of Neuroimmune Pharmacology (2023)
-
Lupus-like Disease in FcγRIIB−/− Mice Induces Osteopenia
Scientific Reports (2019)
-
FcγRIIb differentially regulates pre-immune and germinal center B cell tolerance in mouse and human
Nature Communications (2019)
-
Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model
Cancer Immunology, Immunotherapy (2019)